In patients with TNBC (a typically cold tumor), CD8+CD103+ TRM cells are particularly important for immunotherapy and tend to express higher levels of immune checkpoint molecules, such as PD‐1, CTLA‐4, TIM‐3, and LAG3.139. Here, CD8A is linked to neoplasm.